Volume 8, Issue 4 (11-2022)
Journal of Research in Applied and Basic Medical Sciences 2022, 8(4): 189-195 |
Back to browse issues page
Department of Pharmacology and Toxicology, Niger Delta University, Nigeria , adikwuelias@gmail.com
Abstract: (1024 Views)
Background & Aims: Human immunodeficiency virus (HIV) is a retrovirus belonging to the family of lentiviruses. It is the causative organism of Acquired Immune Deficiency Syndrome (AIDS), which has become one of the greatest public health challenges faced by mankind. Highly Active Antiretroviral Therapy (HAART) has remarkably improved survival and the quality of life of the people living with HIV, but the occurrence of adverse reactions is a serious challenge. This study assessed adverse drug reactions (ADRs) in the people living with HIV on first line HAART attending Federal Medical Centre (FMC), Makurdi, Benue State, Nigeria.
Materials & Methods: In this descriptive-retrospective study, the data of 350 people on HAART attending FMC, Makurdi, Nigeria from 2010 to 2012 were collected, using a structured questionnaire. Data was analyzed using Chi-square with the aid of SPSS v.20 software. A p-value ˂0.05 was considered significant.
Results: HIV infection was more in females (66%) than in males (34%). Adverse Drug Reactions (ADRs) were more in females (60%) than in males (40%). The most prescribed HAART regimens were zidovudine/lamivudine/nevirapine (44.3%), and tenofovir/emtricitabine/nevirapine (31.7%). ADRs were observed in 195 (55.7 %) of the people living with HIV on first line HAART. The observed ADRs were abdominal pain (28.7%), diarrhea (10.8%), vomiting (3.6%), hepatitis (17%), mild skin rash (22%), severe skin rash (4%), anemia (0.4%), peripheral neuropathy (5.4%), insomnia (4.0%), and dizziness (3.6%). Most ADRs were observed in nevirapine based HAART; zidovudine/lamivudine/nevirapine (46.6%) and tenofovir/emtricitabine/nevirapine (32.6%). The nature of the observed ADRs was mild (71.6%), moderate (27.1%) and severe (1.30%).
Conclusion: The use of first line HAART seems safe, because observed ADRs were not severe, but the patients should be routinely monitored for ADRs.
Materials & Methods: In this descriptive-retrospective study, the data of 350 people on HAART attending FMC, Makurdi, Nigeria from 2010 to 2012 were collected, using a structured questionnaire. Data was analyzed using Chi-square with the aid of SPSS v.20 software. A p-value ˂0.05 was considered significant.
Results: HIV infection was more in females (66%) than in males (34%). Adverse Drug Reactions (ADRs) were more in females (60%) than in males (40%). The most prescribed HAART regimens were zidovudine/lamivudine/nevirapine (44.3%), and tenofovir/emtricitabine/nevirapine (31.7%). ADRs were observed in 195 (55.7 %) of the people living with HIV on first line HAART. The observed ADRs were abdominal pain (28.7%), diarrhea (10.8%), vomiting (3.6%), hepatitis (17%), mild skin rash (22%), severe skin rash (4%), anemia (0.4%), peripheral neuropathy (5.4%), insomnia (4.0%), and dizziness (3.6%). Most ADRs were observed in nevirapine based HAART; zidovudine/lamivudine/nevirapine (46.6%) and tenofovir/emtricitabine/nevirapine (32.6%). The nature of the observed ADRs was mild (71.6%), moderate (27.1%) and severe (1.30%).
Conclusion: The use of first line HAART seems safe, because observed ADRs were not severe, but the patients should be routinely monitored for ADRs.
Type of Study: orginal article |
Subject:
General
References
1. Kranick SM, Nath A. Neurologic Complications of HIV-1 Infection and Its Treatment in the Era of Antiretroviral Therapy. Cont Lifelong Learn Neurol 2012;18(6):1319-37 [DOI:10.1212/01.CON.0000423849.24900.ec] [PMID] [PMCID]
2. Lindo JF, Dubon JM, Ager AL, De Gourville EM, Solo-Gabriele H, Klaskala WI, Baum MK, Palmer CJ. Intestinal parasitic infections in human immunodeficiency virus (HIV)-positive and HIV-negative individuals in San Pedro Sula, Honduras. Am J Trop Med Hygiene 1998;58(4):431-5. [DOI:10.4269/ajtmh.1998.58.431] [PMID]
3. Schulz TF, Boshoff CH, Weiss RA. HIV infection and neoplasia. Lancet 1996; 587-91. [DOI:10.1016/S0140-6736(95)11033-X] [PMID]
4. UNAIDS. 2017. Fact sheet July 2017. UNAIDS, Geneva, Switzerland. www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed 11 November 2017 [URL]
5. UNAIDS. 2015. Treatment 2015. UNAIDS, Geneva, Switzerland. www.unaids.org/sites/default/files/media_asset/JC2484_treatment-2015_en _1.pdf. Accessed 7 March 2018. [URL]
6. UNAIDS. 2017. Fact sheet-World AIDS Day 2017. UNAIDS, Geneva, Switzerland. www.unaids.org/sites/default/files/media_asset/UNAIDS _FactSheet_en.pdf. Accessed 2 April 2018. [URL]
7. Parekh BS, Ou CY, Fonjungo PN. Kalou MB, Rottinghaus E, Puren A, et al. Diagnosis of Human Immunodeficiency Virus Infection. Clin Micro Rev 2019;32(1):1-55 [DOI:10.1128/CMR.00064-18] [PMID] [PMCID]
8. Gontran M, Jerome LT, Yvonne AM, Mavoungou-Poaty V, Elie M, Brice O, et al. Effects of IM28 on HIV-1 and Metabolic Disorders-induced Highly Active Antiretroviral Therapy in Gabonese Patients. J Antivir Antiretrovir 2009; 1:76-81. [Google Scholar]
9. Montessori V, Press N, Harris M, Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J 2004;170(2):229-38. [Google Scholar]
10. Subbaraman R, Chaguturu KS, Mayer KH. Adverse Effects of Highly Active Antiretroviral Therapy in Developing Countries. Clin Infec Dis 2007;45(8):1093-101. [DOI:10.1086/521150] [PMID]
11. Victoria NU, Sunday NO. Assessment of highly active antiretroviral therapy (HAART) adherence among HIV patients in a tertiary health institution in Nigeria. Afri J Pharm and Pharm 2014;8(47):1192-9. [Google Scholar]
12. Patel AK, Patel KK. Future implications: Compliance and failure with Future implications: Compliance and failure with antiretroviral treatment antiretroviral treatment antiretroviral treatment. J Postgrad Med 2006;52(3):197-200. [Google Scholar]
13. Uakarn C, Chaokromthong K, Sintao N. Sample Size Estimation using Yamane and Cochran and Krejcie and Morgan and Green Formulas and Cohen Statistical Power Analysis by G*Power and Comparisons. Apheit Intern J 2021;10(2):76-88. [Google Scholar]
14. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. World Health Organization; 2010. [URL]
15. Lartey M, Quashie AA, Essel A, Kenu E, Ganu V, Neequaye A, et al. Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hopital in Ghana. Pan Afr Med J 2014; 18:25. [DOI:10.11604/pamj.2014.18.25.3886] [PMID] [PMCID]
16. Sadiq S, Gupta S, Khajuria V, Tandon VR, Mahajan A, Gupta M. et al. Adverse drug events due to Antiretroviral Therapy in a Northern Indian Tertiary Care Institution. Natl J Physiol Pharm Pharm 2016; 6:205-8 [DOI:10.5455/njppp.2016.6.31012016114]
17. Abdela J, Assefa A, Shamele S. Prevalence of Adverse Drug Reactions among Pediatric Patients on Antiretroviral Therapy in Selected Hospitals in Eastern Ethiopia: 8-Year Retrospective Cross-Sectional Study. J Int Ass Provider AIDS Care 2019; 18:1-7. [DOI:10.1177/2325958218823208] [PMID] [PMCID]
18. Eluwa GI, Badru T, Akpoigbe KJ. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharm 2012; 12:7.
https://doi.org/10.1186/1472-6904-12-14 [DOI:10.1186/1472-6904-12-7] [PMCID]
19. Sharma A, Vora R, Modi M. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol 2008;74(3):234-7. [DOI:10.4103/0378-6323.41368] [PMID]
20. Menezez de Pádua CA, César CC, Bonolo PF. High incidence of adverse reactions to intial antiretroviral therapy in Brazil. Braz J Med Biol Res 2006; 39:495-505. [DOI:10.1590/S0100-879X2006000400010] [PMID]
21. Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, Bernasconi E et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther 2007; 12:1157-64. [DOI:10.1177/135965350701200808] [PMID]
22. Oshikoya KA, Lawal S, Oreagba IA. Adverse Events in HIV-infected Children on Antiretroviral Therapy at a Teaching Hospital in Lagos, Nigeria: A Retrospective Study. Adv Pharmacoepidem Drug Saf 2012; 1:117. [Google Scholar]
23. Obiako OR, Haruna MM, Sani GB, Eric T, Adebola OT, Mathew I et al. Adverse reactions associated with antiretroviral regimens in adult patients of a university teaching hospital HIV program in Zaria, Northern Nigeria: an observational cohort study. J Antivir Antiretrovir 2012; 4:6-13. [Google Scholar]
24. Verweel G, Sharland M, Lyall H, Novelli V, Gibb DM, Dumont G, et al. Nevirapine use in HIV-1- infected children. AIDS 2003; 17:1639-47. [DOI:10.1097/00002030-200307250-00008] [PMID]
25. Arisudhana GB, Sofro MU, Sujianto U. Antiretroviral Side Effects on Adherence in People Living with HIV/AIDS. Nurse Media J Nurs 2018;8(2):79-85 [DOI:10.14710/nmjn.v8i2.20742]
26. Ezhilarasan D, Srilekha M, Raghu R. HAART and Hepatotoxicity. J App Pharm Sci 2017;7(04):220-6. [Google Scholar]
27. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD Hepatotoxicity Associated With Nevirapine or Efavirenz-Containing Antiretroviral Therapy: Role of Hepatitis C and B Infections. Hep 2002; 35:182-9 [DOI:10.1053/jhep.2002.30319] [PMID]
28. Pryce C, Pierre RB, Steel-Duncan J, Evans-Gilbert T, Palmer P, et al. Safety of antiretroviral drug therapy in Jamaican children with HIV/AIDS. West Indian Med J 2008; 57:238-45. [Google Scholar]
29. Shah I. Adverse effects of antiretroviral therapy in HIV-1- infected children. J Trop Ped 2006; 52:244-8. [DOI:10.1093/tropej/fmi086] [PMID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |